source
- AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapiesAbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
- AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor dealAbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…